Research programme: protease inhibitors - Jiangsu Hengrui/Medivir

Drug Profile

Research programme: protease inhibitors - Jiangsu Hengrui/Medivir

Latest Information Update: 22 Feb 2007

Price : $50

At a glance

  • Originator Jiangsu Hengrui Medicine Co.; Medivir AB
  • Class
  • Mechanism of Action Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Chronic obstructive pulmonary disease

Most Recent Events

  • 22 Feb 2007 Medivir and Jiangsu Hengrui Medicine Co. extend research collaboration
  • 18 Feb 2005 This programme is still in active development
  • 30 Nov 2003 Preclinical trials in Chronic obstructive pulmonary disease in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top